原武直紀 (Naoki Haratake) - マイポータル

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)

Kazuki Hayasaka, Mototsugu Shimokawa, Naoki Haratake, Hirotsugu Notsuda, Shinya Katsumata, Akira Hamada, Kotaro Nomura, Kosuke Fujino, Mao Yoshikawa, Ken Suzawa …

Lung Cancer 212 108908-108908 2026年2月

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, Chie Kikutake, Hiroki Ozawa, Keisuke Shigeta, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa, Mikita Suyama …

Signal transduction and targeted therapy 10(1) 389-389 2025年11月28日

Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR Study.

Hironobu Hoshino, Shinya Katsumata, Akira Hamada, Naoki Haratake, Kyoshiro Takegahara, Shoko Nakasone, Hidenori Kawasaki, Mototsugu Shimokawa, Satoshi Shiono, Junichi Soh …

Pathology international 75(9) 451-458 2025年9月

Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.

Naoki Haratake, Shinkichi Takamori, Hideko Isozaki, Keisuke Shigeta, Chie Kikutake, Hiroki Ozawa, Atrayee Bhattacharya, Ayako Nakashoji, Mikita Suyama, Tomoyoshi Takenaka …

Cell death discovery 11(1) 372-372 2025年8月8日

Identification of MUC1-C Dependence in Drug-Resistant Advanced Prostate Cancer Uncovers a Target for Antibody-Drug Conjugate Therapy.

Keisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, Ayako Nakashoji, Atrayee Bhattacharya, Shinkichi Takamori …

JCI insight 2025年6月24日査読有り

MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.

Ayako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa, Naoki Haratake, Keisuke Shigeta, Atsushi Fushimi, Nami Yamashita, Akira Matsui, Shoko Kure, Tomoe Kameyama …

NPJ breast cancer 11(1) 39-39 2025年4月26日査読有り

Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).

Kotaro Nomura, Kazuki Takada, Fumihiko Kinoshita, Satoshi Muto, Taichi Matsubara, Yasunobu Kouki, Shinya Katsumata, Akira Hamada, Naoki Haratake, Kosuke Fujino …

International journal of cancer 156(7) 1480-1491 2025年4月1日査読有り

Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa …

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20(3) 399-399 2025年3月

Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".

Naoki Haratake, Donald Kufe

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 19(12) e88-e89 2024年12月査読有り筆頭著者

MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer.

Hiroki Ozawa, Naoki Haratake, Ayako Nakashoji, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Keisuke Shigeta, Atsushi Fushimi, Kazumasa Fukuda, Yohei Masugi …

Biomedicines 12(7) 2024年7月8日査読有り

MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.

Atrayee Bhattacharya, Keyi Wang, Johany Penailillo, Chi Ngai Chan, Atsushi Fushimi, Nami Yamashita, Tatsuaki Daimon, Naoki Haratake, Hiroki Ozawa, Ayako Nakashoji …

Oncogene 43(28) 2199-2214 2024年7月査読有り

Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas.

Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi …

Cancer research communications 4(5) 1268-1281 2024年5月14日査読有り

XIST and MUC1-C form an auto-regulatory pathway in driving cancer progression.

Keyi Wang, Atrayee Bhattacharya, Naoki Haratake, Tatsuaki Daimon, Ayako Nakashoji, Hiroki Ozawa, Bo Peng, Wei Li, Donald Kufe

Cell death & disease 15(5) 330-330 2024年5月13日査読有り

Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.

Shinya Katsumata, Mototsugu Shimokawa, Akira Hamada, Naoki Haratake, Kotaro Nomura, Kosuke Fujino, Mao Yoshikawa, Ken Suzawa, Kazuhiko Shien, Kenichi Suda …

European journal of cancer (Oxford, England : 1990) 201 113951-113951 2024年4月査読有り

Abstract 3279: MUC1 is necessary for the inflammatory memory response to osimertinib resistance in NSCLC cells

Naoki Haratake, Atrayee Bhattacharya, Ayako Nakashoji, Hiroki Ozawa, Mototsugu Shimokawa, Donald Kufe

Cancer Research 84(6_Supplement) 3279-3279 2024年3月22日査読有り筆頭著者

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa …

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 19(3) 434-450 2024年3月査読有り筆頭著者

MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells.

Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Naoki Haratake, Ayako Nakashoji, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Takeo Kosaka, Mototsugu Oya …

Cell death discovery 10(1) 9-9 2024年1月5日査読有り

原武直紀

基本情報

論文

メニュー